Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Tuesday that the first patient treated with its cancer drug FT500...
Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $20. Price: 16.71, Change: -0.10, Percent Change: -0.59...
Fate Therapeutics (FATE) reported a net loss of $0.25 per share for Q4 from a loss of $0.29 a year earlier, but that was wider than the consensus on...
Expected Earnings Release: 03/05/2019, After-hours Avg. Extended-Hours Dollar Volume: $356,938 FATE THERAPEUTC (FATE) is due to issue its quarterly...
| Address | 3535 General Atomics Court San Diego, California 92121 |
| Phone | +1.858.875.1800 |
| Number of Employees | 104 |
| Recent SEC Filing | 04/08/2019 DEFA14A |
| President, Chief Executive Officer & Director | J. Scott Wolchko |
| Chief Scientific Officer | Daniel D. Shoemaker |
| Senior Vice President-Corporate Development | Jim Beitel |
| Chief Development Officer | Bahram Valamehr |
| Price Open | $16.52 |
| Previous Close | $15.61 |
| 52 Week Range | $8.35 - 19.11 |
| Market Capitalization | $1.0 B |
| Shares Outstanding | 65.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 05/09/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $4.7 M |
| Net Profit Margin | -1,405.02% |
| Return on Equity | -59.04% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
